More Ranbaxy woes

Share this article:

The FDA has put Ranbaxy Laboratories on notice.

Again.

Bloomberg reports that the US regulator says a recent inspection shows a Punjab, India, plant that makes 60% to 70% of the company's active ingredients is failing to make the grade.

The company agreed to shell out $500 million over fraud allegations in May, and Bloomberg notes that the US has already banned items from three Ranbaxy plants from entering the country.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.